Cassava Sciences Files 8-K
Ticker: FLNA · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Cassava Sciences filed an 8-K on 4/15/24. No specific details yet.
AI Summary
Cassava Sciences, Inc. filed an 8-K on April 15, 2024, reporting other events and financial statements. The company, previously known as Pain Therapeutics Inc., is incorporated in Delaware and headquartered in Austin, Texas. This filing does not contain specific financial figures or details about the 'other events' reported.
Why It Matters
This 8-K filing indicates that Cassava Sciences has made a regulatory submission, which could contain important updates regarding their business operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, without immediate material financial disclosures or significant operational changes detailed within the provided text.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- Pain Therapeutics Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Austin, Texas (location) — Principal Executive Offices
- April 15, 2024 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported.
What is the primary purpose of this 8-K filing for Cassava Sciences?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of April 15, 2024.
When was Cassava Sciences, Inc. previously known?
Cassava Sciences, Inc. was formerly known as Pain Therapeutics Inc., with a date of name change on March 9, 2000.
Where are Cassava Sciences, Inc.'s principal executive offices located?
The principal executive offices of Cassava Sciences, Inc. are located at 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
What is the SEC file number for Cassava Sciences, Inc.?
The SEC file number for Cassava Sciences, Inc. is 001-41905.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-04-15 16:01:14
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- f8k_041524.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-24-002020.txt ( ) — 225KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_041524_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On April 15, 2024, Cassava Sciences, Inc., a Delaware corporation (the "Company"), issued a press release announcing that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the "Warrants"). Any Warrants that are not validly exercised by 5:00 p.m. New York City time on May 6, 2024 will be redeemed by the Company on May 7, 2024 (the "Redemption Date") for a nominal payment of $0.001 per warrant (the "Redemption Price"). Once redeemed, the Warrants will cease to exist and have no value. The foregoing description is only a summary and is qualified in its entirety by reference to the press release, which is filed as an exhibit to this Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated April 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cassava Sciences, Inc. Date: April 15, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer